Budget Impact of Prophylactic Letermovir to Prevent Cytomegalovirus Disease in High-Risk Adult Kidney Transplant Recipients. (PubMed, Pharmacoecon Open) - Sep 13, 2026 - "This analysis provides evidence on the potential impact of introducing letermovir into the US market. While the acquisition cost of letermovir is higher than that of VGCV, there are estimated cost savings, primarily driven by the prevention of LN events and their associated downstream clinical consequences, suggesting that the savings from LN avoidance outweigh the incremental prophylaxis costs of introducing letermovir. However, the overall budget impact remains minimal and should be interpreted in the context of the evolving evidence base."
HEOR • Journal • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Leukopenia • Neutropenia • Transplant Rejection • Transplantation
|
|
Abdel Hmissi; Andrew Beyer; Irina Kolobova; Lei Ai; Michael Wong; Murvin Jootun; Qinghua Li; Vladimir Turzhitsky
|